The PE Ratio as of November 2024 (TTM) for 2seventy bio, Inc. (TSVT) is -1.47

According to 2seventy bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.47. This represents a change of 504.57% compared to the average of -0.24 of the last 4 quarters.

2seventy bio, Inc. (TSVT) Historical PE Ratio (quarterly & annually)

How has TSVT PE Ratio performed in the past?

The mean historical PE Ratio of 2seventy bio, Inc. over the last ten years is -1.56. The current -1.47 PE Ratio has changed 9.30% with respect to the historical average. Over the past ten years (40 quarters), TSVT's PE Ratio was at its highest in in the March 2020 quarter at 5.57. The PE Ratio was at its lowest in in the December 2022 quarter at -3.92.

2seventy bio, Inc. (TSVT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of 2seventy bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

2seventy bio, Inc. (TSVT) Average PE Ratio

How has TSVT PE Ratio performed in the past?

The current PE Ratio of 2seventy bio, Inc. (TSVT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

2seventy bio, Inc. (TSVT) PE Ratio vs. Peers

How is TSVT’s PE Ratio compared to its peers?

2seventy bio, Inc.’s PE Ratio is greater than Intercept Pharmaceuticals, Inc. (-13.55), less than Puma Biotechnology, Inc. (16.34), greater than Iovance Biotherapeutics, Inc. (-7.40), less than Sarepta Therapeutics, Inc. (246.20), greater than Day One Biopharmaceuticals, Inc. (-17.12), greater than Inozyme Pharma, Inc. (-3.09), less than Zentalis Pharmaceuticals, Inc. (-1.36), greater than Syndax Pharmaceuticals, Inc. (-6.12), less than Protagonist Therapeutics, Inc. (16.87), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Cullinan Oncology, Inc. (-6.16), greater than Mersana Therapeutics, Inc. (-2.13), greater than Relay Therapeutics, Inc. (-2.41), greater than Arcus Biosciences, Inc. (-5.69), greater than Stoke Therapeutics, Inc. (-7.05), greater than Kezar Life Sciences, Inc. (-5.24), greater than Phathom Pharmaceuticals, Inc. (-3.73), greater than Replimune Group, Inc. (-3.78), greater than Chinook Therapeutics, Inc. (-11.89), greater than DICE Therapeutics, Inc. (-23.17), greater than Pliant Therapeutics, Inc. (-4.72), greater than Crinetics Pharmaceuticals, Inc. (-17.36), greater than Ascendis Pharma A/S (-13.51),

Build a custom stock screener for 2seventy bio, Inc. (TSVT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 2seventy bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

2seventy bio, Inc. (TSVT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like 2seventy bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.